

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

  
\_\_\_\_\_  
Signature of Authorized Individual\*

8/20/2020  
Date

  
\_\_\_\_\_  
Printed Name of Authorized Individual

8/20/2020  
Date

\*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

**SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)**

Case No.	Debtor Entity Name:	Net Receipts <sup>2</sup>	Net Disbursements <sup>1</sup>
19-23648	PURDUE PHARMA INC.	\$ 130,465	\$ 441,667
19-23649	PURDUE PHARMA L.P.	108,179,659	98,457,101
19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	-
19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	17,458
19-23652	PURDUE PHARMACEUTICALS L.P.	-	3,282,665
19-23653	IMBRIUM THERAPEUTICS L.P.	-	1,798,843
19-23654	ADLON THERAPEUTICS L.P.	-	2,570,757
19-23655	GREENFIELD BIO VENTURES L.P.	-	463,485
19-23656	SEVEN SEAS HILL CORP.	-	-
19-23657	OPHIR GREEN CORP.	-	-
19-23658	PURDUE PHARMA OF PUERTO RICO	-	1,356
19-23659	AVRIO HEALTH L.P.	1,800	5,597,375
19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	46,425
19-23661	PURDUE NEUROSCIENCE COMPANY	-	-
19-23662	NAYATT COVE LIFESCIENCE INC.	-	784,930
19-23663	BUTTON LAND L.P.	-	-
19-23664	PAUL LAND INC.	-	-
19-23665	QUIDNICK LAND L.P.	-	-
19-23666	RHODES ASSOCIATES L.P.	-	-
19-23667	RHODES PHARMACEUTICALS L.P.	12,865,738	13,355,118
19-23668	RHODES TECHNOLOGIES	774,907	4,848,842
19-23669	UDF LP	-	-
19-23670	SVC PHARMA LP	-	627,459
19-23671	SVC PHARMA INC.	-	-
<b>Totals:</b>		<b>\$ 121,952,569</b>	<b>\$ 132,293,481</b>

**Footnotes**

1) The Net Disbursements exclude intercompany transactions among Debtors

2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
July 31, 2020

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	\$ 750,229
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,864,641
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,025,086
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	3,508,752
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,664,151
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Money Market Account	201,279,741
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Money Market Account	100,296,603
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx8720	Money Market Account	100,191,085
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	53,823,823
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	578,568,044
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	15,930,561
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	219,966
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx6017	Trust	15,148,562
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,272,739
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	59,176,975
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,017,014
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	122,884,045
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,391,183
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx4018	Trust	25,104,855
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	1,187,846
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	125,942
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
July 31, 2020

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-
Rhodes Technologies	JP Morgan Chase	xxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
<b>Total</b>				<b>\$ 1,333,782,506</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

**CONSOLIDATED STATEMENT OF OPERATIONS (\$M)** <sup>1,2</sup>  
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Net Sales	\$ 90	\$ 562	\$ 873
Cost of Goods Sold	(19)	(113)	(213)
Gross Profit	71	449	659
Sales and Promotion	(8)	(62)	(100)
Research and Development	(6)	(41)	(75)
General and Administrative	(8)	(56)	(96)
Legal Fees - Ordinary Course	(2)	(7)	(10)
Medical Affairs	(3)	(18)	(29)
Milestones & Alliances	-	(5)	(6)
Health Care Reform Fee	(1)	(7)	(11)
Other US	(1)	(2)	(3)
Incentive Bonus	(3)	(24)	(40)
Total Operating Expenses	(32)	(222)	(370)
Operating Profit	39	227	290
Legal Fees - Non-Recurring	(29)	(209)	(306)
Other	(1)	(12)	(19)
Total Non-Operating Expenses	(30)	(221)	(325)
Profit	\$ 9	\$ 6	\$ (35)

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000) <sup>1,2</sup>

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Management Fee Income	\$ 29	\$ 204	\$ 319
General and Administrative Expenses	-	(23)	(52)
Operating Income	29	181	267
		-	
Income from Unconsolidated Associated Companies	(244)	5	(921)
Total Other Income	(244)	5	(921)
		-	
Pre-Tax Income	(215)	186	(654)
		-	
Income Tax Provision	58	(50)	162
		-	
Net Income	\$ (157)	\$ 136	\$ (492)

Footnotes

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
July 31, 2020

CONSOLIDATED BALANCE SHEET (\$M) <sup>1,2</sup>	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
<b>ASSETS</b>	
<b>CURRENT ASSETS</b>	
Cash & Cash Equivalents	\$ 1,051
Available For Sale Investments	1
Accounts Receivable, Net	105
Due From Associated Companies	8
Other Receivables	2
Inventories, Net	112
Prepaid Expenses & Other Current Assets	66
Restricted Cash	136
<b>TOTAL CURRENT ASSETS</b>	<b>1,481</b>
Property and Equipment, net	134
Investments at Cost	37
Investments in Associated Companies	-
Restricted Cash - Long-Term	147
Intangible Assets, Net	97
Other Assets	3
<b>TOTAL ASSETS</b>	<b>\$ 1,899</b>
<b>LIABILITIES AND EQUITY</b>	
<b>CURRENT LIABILITIES</b>	
Accounts Payable	\$ 43
Accrued Expenses	341
Due to Associated Companies	1
<b>TOTAL CURRENT LIABILITIES</b>	<b>385</b>
Other Liabilities	97
Due to Associated Companies	11
Liabilities Subject to Compromise <sup>3</sup>	3,016
<b>TOTAL LIABILITIES</b>	<b>3,509</b>
<b>EQUITY</b>	
Retained Earnings & Partners' Capital	(1,564)
Accumulated Other Comprehensive Loss	(46)
<b>TOTAL EQUITY</b>	<b>(1,610)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$ 1,899</b>

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
July 31, 2020

**PURDUE PHARMA, INC. BALANCE SHEET (\$000) <sup>1,2</sup>**

	Book Value	
<b>Assets</b>		
Currents assets:		
Cash and cash equivalents	\$	1,188
Prepaid expenses		312
Due from Associated Companies		31
Other receivables		-
<b>Total current assets</b>		<b>1,531</b>
Investments		10,326
Deferred income taxes		147
<b>Total assets</b>	<b>\$</b>	<b>12,004</b>
<b>Liabilities and equity</b>		
Current liabilities:		
Accounts payable	\$	463
Due to Associated Companies		175
Accrued Expenses		178
<b>Total liabilities</b>		<b>816</b>
Common stock		1
Additional paid-in capital		499
Retained earnings		10,753
Accumulated other comprehensive loss		(65)
<b>Total equity</b>		<b>11,188</b>
<b>Total liabilities and equity</b>	<b>\$</b>	<b>12,004</b>

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

**SCHEDULE OF POST PETITION TAXES**

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



\_\_\_\_\_  
Signature

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Compensation</b>		
Chomiak, Caroline	\$ -	\$ 261,662
Kesselman, Marc L <sup>2</sup>	1,068,504	3,691,842
Landau, Craig J	244,364	2,624,837
Lowne, Jonathan R	495,090	1,726,788
Lundie, David R	410,437	1,418,505
Mancinelli II, Vincent F	220,790	811,988
Mazzi, Christian	-	439,030
Medeiros, Paul	311,123	1,108,280
Shamblen, Randy	218,141	798,984
Strassburger, Philip C	379,136	1,432,408
<b>Total Compensation</b>	<b>3,347,586</b>	<b>14,314,324</b>
<b>Director Fees</b>		
Boer, F Peter	-	700,000
Buckfire, Kenneth A	-	700,000
Cola, Michael	-	700,000
Collins, Michael J	-	25,000
Dubel, John	-	700,000
Miller, Robert S	208,333	1,875,000
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	-	700,000
<b>Total Director Fees</b>	<b>208,333</b>	<b>5,425,000</b>
<b>T&amp;E Reimbursements</b>		
Boer, F Peter	-	10,907
Buckfire, Kenneth A	-	1,565
Chomiak, Caroline	-	30,408
Cola, Michael	-	1,388
Debone, Louis	-	1,245
Dubel, John	-	4,714
Kesselman, Marc L	50	49,415
Landau, Craig J	614	65,726
Lowne, Jonathan R	70	1,834
Lundie, David R	-	28,913
Mancinelli II, Vincent F	39	41,279
Mazzi, Christian	-	3,734
Medeiros, Paul	-	36,103
Miller, Robert S	-	9,765
Pickett, Cecil	-	1,298
Shamblen, Randy	39	11,509
Strassburger, Philip C	-	15,995
<b>Total T&amp;E Reimbursements</b>	<b>812</b>	<b>315,797</b>
<b>Housing Payments</b>		
Kesselman, Marc L	4,673	55,849
<b>Total Housing Payments</b>	<b>4,673</b>	<b>55,849</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Indemnification Payments</b>		
Baker, Stuart D <sup>3</sup>	(387)	811,088
Butcher, James A	-	527
Friedman, Michael	10,977	147,842
Landau, Craig J	166,077	1,121,878
Motahari, Saeed	-	24,208
Roncalli, Anthony	71,308	286,951
Stewart, John	-	135,125
Timney, Mark	11,004	1,047,342
Purdue Pharma Inc Independent Directors <sup>4</sup>	178,921	1,132,033
<b>Total Indemnification Payments</b>	<b>437,899</b>	<b>4,706,995</b>
<b>Payments to Independent Associated Companies</b>		
Mundibiopharma Ltd	-	55,332
Mundipharma DC BV	-	263,503
Mundipharma International Technical Operations Ltd.	-	4,479
Mundipharma IT Services LTD	-	278,603
Mundipharma Laboratories GmbH	137,744	821,537
Mundipharma Research LTD	50,276	113,807
Mundipharma Singapore Holdings Pte Ltd	-	60,675
One Stamford Realty L.P.	3,571,159	11,026,286
Pharmaceutical Research Associates Inc.	471,849	957,382
Purdue Pharma Canada	552,005	3,963,639
TXP Services Inc. <sup>5</sup>	1,040,759	6,503,279
<b>Total Payments to Independent Associated Companies</b>	<b>5,823,792</b>	<b>24,048,521</b>
<b>Total Payments to Insiders</b>	<b>\$ 9,823,096</b>	<b>\$ 48,866,486</b>

**Footnotes**

1) Represents payments made since the Commencement Date.

2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.

3) Indemnification payments made in June 2020 on behalf of Stuart D. Baker were inadvertently in amounts exceeding the 50% reimbursement rate approved by the Special Committee of Purdue Pharma Inc.'s Board of Directors, totaling \$12,390. Overpayments are being reversed through future invoice credits, repayment from respective law firms, and/or reimbursement from Stuart D. Baker.

4) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snyderman, Ralph.

5) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1,2</sup>
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	\$ 4,278,185	\$ 39,911,467
AlixPartners, LLP	1,198,375	9,710,539
PJT Partners LP	553,908	1,540,365
Ernst & Young	40,000	520,000
Prime Clerk LLC	2,142,996	41,779,740
<b>Total Estate Professionals</b>	<b>8,213,464</b>	<b>93,462,110</b>
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	9,494,034	24,165,067
Bayard, P.A.	-	768,164
Cole Schotz P.C.	1,317,686	2,028,511
Jefferies LLC	364,224	1,546,860
KPMG	1,037,979	1,863,330
Province, Inc.	2,674,827	8,509,142
Kurtzman Carson Consultants LLC	66,213	117,705
<b>Total Creditor Committee Professionals</b>	<b>14,954,963</b>	<b>38,998,780</b>
<i>Ad Hoc Committee Professionals</i>		
Kramer Levin Naftalis & Frankel LLP	856,473	3,361,642
Brown Rudnick LLP	422,159	1,757,329
Gilbert LLP	965,718	1,836,219
Otterbourg PC	180,345	908,459
FTI Consulting, Inc	606,613	4,460,605
Compass Lexecon	-	-
Coulter & Justice	-	-
<b>Total Ad Hoc Committee Professionals</b>	<b>3,031,308</b>	<b>12,324,254</b>
<i>Special Counsel to the Debtors</i>		
Arnold Porter & Kaye Scholer	249,975	1,076,369
Dechert LLP	-	-
Jones Day	205,838	1,322,561
King & Spalding LLP	2,742,746	9,038,828
Skadden, Arps, Slate, Meagher & Flom LLP	3,708,833	6,994,784
Wilmer Cutler Pickering Hale and Door LLP	646,383	646,383
<b>Total Special Counsel Professionals</b>	<b>7,553,775</b>	<b>19,078,925</b>
<b>The Law Offices of Kenneth Feinberg (Mediator)</b>	<b>500,000</b>	<b>2,502,648</b>
<b>Phillips ADR (Mediator)</b>	<b>500,000</b>	<b>2,504,089</b>
<b>Bielli &amp; Klauder, LLC (Fee Examiner)</b>	<b>-</b>	<b>-</b>
<b>Tom Vilsack (Court appointed monitor)</b>	<b>23,375</b>	<b>93,250</b>
<b>Ernst &amp; Young (Canada), Court Appointed Information Officer</b>	<b>19,955</b>	<b>198,546</b>
<b>Total Retained Restructuring Professional Fees</b>	<b>\$ 34,796,840</b>	<b>\$ 169,162,602</b>

Footnotes

- 1) Represents payments made since the Commencement Date
- 2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period July 1, 2020 to July 31, 2020

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?		X	
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	